Vantage logo

Treme climbs a new mountain

Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.

Vantage logo

Reneuron’s reinvention falters

More data with the group’s retinal stem cells have disappointed, but the company brushed off two cases of vision loss.